BioMarin Pharmaceuticals BMRN Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's business segments — net income?
- BioMarin Pharmaceuticals (BMRN) reported business segments — net income of $105.53M in Q1 2026.
- How has BioMarin Pharmaceuticals's business segments — net income changed year-over-year?
- BioMarin Pharmaceuticals's business segments — net income decreased by 43.2% year-over-year, from $185.69M to $105.53M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — net income?
- Over 2 years (2022 to 2024), BioMarin Pharmaceuticals's business segments — net income has grown at a 73.6% compound annual growth rate (CAGR), from $141.56M to $426.86M.
- What does business segments — net income mean?
- The total profit or loss generated by the business segment after all related expenses.
- How do you interpret business segments — net income?
- An increase signifies improved profitability and operational success, while a decrease suggests rising costs or declining revenue performance.
- How does business segments — net income compare across companies?
- Comparable to segment operating profit or net income reported by peer pharmaceutical companies.